血清抗核抗体滴度与代谢相关脂肪性肝病临床病理特征的相关性研究

肝脏 ›› 2026, Vol. 31 ›› Issue (5): 668-672.

血清抗核抗体滴度与代谢相关脂肪性肝病临床病理特征的相关性研究

王晓明, 郭甜甜, 常柳祎, 罗娟, 王宇, 欧晓娟, 贾继东, 赵新颜

100050 北京首都医科大学附属北京友谊医院肝病研究中心,国家消化系统疾病临床医学研究中心,全国消化健康重点实验室(王晓明,郭甜甜,王宇,欧晓娟,贾继东,赵新颜);
044000 运城山西省运城市中心医院(常柳祎);
065000 廊坊河北中石油中心医院(罗娟)

收稿日期:2025-09-10 发布日期:2026-07-10
基金资助:
国家临床重点专科建设项目(2022年感染性疾病科)

Correlation study between serum antinuclear antibody and pathological characteristics of metabolic associated fatty liver disease

WANG Xiao-ming¹, GUO Tian-tian¹, CHANG Liu-yi², LUO Juan³, WANG Yu¹, OU Xiao-juan¹, JIA Ji-dong¹, ZHAO Xin-yan¹

1. Liver Research Center Beijing Friendship Hospital, Capital Medical University, Beijing 10050, China;
2. Yuncheng Central Hospital, Gastroenterology Department, Shanxi Medical University, Yuncheng 044000, China;
3. Hebei PetroChina Central Hospital, Langfang 065000, China

Received:2025-09-10 Published:2026-07-10

摘要/Abstract

摘要： 目的探讨血清抗核抗体(ANA)滴度与代谢相关脂肪性肝病(MAFLD)临床病理特征及免疫指标的相关性。方法纳入2015年1月至2021年12月首都医科大学附属北京友谊医院经肝穿刺病理确诊的133例MAFLD患者,排除其他肝病。检测ANA滴度(≥1∶80为阳性),分析其与小叶炎症、肝细胞气球样变、脂肪变性、肝纤维化程度、NAS评分及免疫球蛋白G(IgG)的关系。结果 ANA阳性率为75.9%(101例),其中1∶80占61.4%,1∶160占27.7%,≥1∶320占10.9%。ANA阳性组女性比例更高(72.3% vs.40.6%, P<0.001),ANA高滴度组平均年龄显著增加(P<0.001)。高滴度组(ANA≥1∶160)肝细胞气球样变分级显著高于低滴度组(ANA≤1∶80)(P=0.017),IgG水平更高(1 663.81±333.07) vs.(1 352.92±380.80)mg/dL(P<0.001)。小叶炎症分级(P=0.065)、脂肪变性程度(P=0.148)、NAS评分(P=0.484)及肝纤维化分期(P=0.229)在两组间差异无统计学意义。结论 ANA滴度与MAFLD患者肝细胞气球样变程度及IgG水平相关,但与小叶炎症、NAS评分、脂肪变性及肝纤维化无显著关联。ANA可能参与肝细胞损伤的免疫机制,但对疾病进展的影响需进一步研究。

关键词: 代谢相关脂肪性肝病, 抗核抗体, 病理特征, 免疫球蛋白G

Abstract: Objective To assess the association of serum antinuclear antibody (ANA) titers with clinicopathological features and immune indicators in patients with metabolic associated fatty liver disease (MAFLD). Methods We enrolled 133 biopsy-confirmed MAFLD patients at Beijing Friendship Hospital from January 2015 to December 2021, excluding those with other liver diseases. ANA titers (≥1∶80 considered positive) were measured. The relationships between ANA titer and lobular inflammation, hepatocyte ballooning, steatosis grade, NAFLD Activity Score (NAS), liver fibrosis grade and IgG levels were analyzed. Results ANA positivity (≥1∶80) was found in 75.9% (101/133) of patients, with titers of 1∶80 in 61.4%, 1∶160 in 27.7%, and ≥1∶320 in 10.9%. ANA-positive patients were more often female (72.3% vs. 40.6%, P<0.001) and older (P<0.001). High-titer patients (ANA≥1∶160, n=38) had higher hepatocyte ballooning scores (P=0.017) and IgG levels (1 664±333 vs. 1 353±381 mg/dL, P<0.001) compared to low-titer patients (ANA≤1∶80, n=95). No significant differences were observed in lobular inflammation, steatosis, NAS or fibrosis stage between groups (all P>0.05). Conclusion Higher ANA titers are associated with increased hepatocyte ballooning and elevated IgG levels in MAFLD, but not with inflammation, steatosis, NAS or fibrosis. ANA may contribute to immune-mediated hepatocyte injury, warranting further investigation into its role in disease progression.

Key words: Metabolic associated fatty liver disease, Antinuclear antibody, Pathological features, Immunoglobulin G

王晓明, 郭甜甜, 常柳祎, 罗娟, 王宇, 欧晓娟, 贾继东, 赵新颜. 血清抗核抗体滴度与代谢相关脂肪性肝病临床病理特征的相关性研究[J]. 肝脏, 2026, 31(5): 668-672.

WANG Xiao-ming, GUO Tian-tian, CHANG Liu-yi, LUO Juan, WANG Yu, OU Xiao-juan, JIA Ji-dong, ZHAO Xin-yan. Correlation study between serum antinuclear antibody and pathological characteristics of metabolic associated fatty liver disease[J]. Chinese Hepatolgy, 2026, 31(5): 668-672.

/ 推荐

参考文献

[1] Fan J G, Kim S U, Wong V W. New trends on obesity and NAFLD in Asia[J]. J Hepatol, 2017, 67(4):862-873.
[2] Riazi K, Azhari H, Charette J H, et al. The prevalence and incidence of NAFLD worldwide:a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7(9):851-861.
[3] Amini-Salehi E, Letafatkar N, Norouzi N, et al. Global prevalence of nonalcoholic fatty liver disease:an updated review meta-analysis comprising a population of 78 million from 38 countries[J]. Arch Med Res, 2024, 55(6):103043.
[4] Buzzetti E, Pinzani M, Tsochatzis E A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65(8):1038-1048.
[5] Cotler S J, Kanji K, Keshavarzian A, et al. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis[J]. J Clin Gastroenterol, 2004, 38(9):801-804.
[6] Ravi S, Shoreibah M, Raff E, et al. Autoimmune markers do not impact clinical presentation or natural history of steatohepatitis-related liver disease[J]. Dig Dis Sci, 2015, 60(12):3788-3793.
[7] Loria P, Lonardo A, Leonardi F, et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease:prevalence and correlates[J]. Dig Dis Sci, 2003, 48(11):2173-2181.
[8] Younes R, Govaere O, Petta S, et al. Presence of serum antinuclear antibodies does not impact long-term outcomes in nonalcoholic fatty liver disease[J]. Am J Gastroenterol, 2020, 115(8):1289-1292.
[9] Zhou Y, Zheng K, Ma H, et al. Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD[J]. Nutr Metab Cardiovasc Dis, 2021, 31(2):552-560.
[10] Adams L A, Lindor K D, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease[J]. Am J Gastroenterol, 2004, 99(7):1316-1320.
[11] Yodoshi T, Orkin S, Arce-Clachar A C, et al. Significance of autoantibody seropositivity in children with obesity and non-alcoholic fatty liver disease[J]. Pediatr Obes, 2021, 16(4):e12696.
[12] Vuppalanchi R, Gould R J, Wilson L A, et al. Clinical significance of serum autoantibodies in patients with NAFLD:results from the nonalcoholic steatohepatitis clinical research network[J]. Hepatol Int, 2012, 6(1):379-385.
[13] Luo L, Ma Q, Lin L, et al. Prevalence and significance of antinuclear antibodies in biopsy-proven nonalcoholic fatty liver disease:a systematic review and meta-analysis[J]. Dis Markers, 2022:8446170.
[14] Jain K, Rastogi A, Thomas S S. Autoantibodies in nonalcoholic fatty liver disease:a systematic review[J]. J Clin Exp Hepatol, 2023, 13(5):730-735.
[15] Chakraborty B, Byemerwa J, Krebs T, et al. Estrogen receptor signaling in the immune system[J]. Endocr Rev, 2023, 44(1):117-141.
[16] Patel S, Homaei A, Raju A B, et al. Estrogen:the necessary evil for human health, and ways to tame it[J]. Biomed Pharmacother, 2018, 102:403-411.
[17] Wilkinson N M, Chen H C, Lechner M G, et al. Sex differences in immunity[J]. Annu Rev Immunol, 2022, 40:75-94.
[18] Di Florio D N, Sin J, Coronado M J, et al. Sex differences in inflammation, redox biology, mitochondria and autoimmunity[J]. Redox Biol, 2020, 31:101482.
[19] Petta S, Grimaudo S, Cammà C, et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2012, 56(6):1356-1362.
[20] Niwa H, Sasaki M, Haratake J, et al. Clinicopathological significance of antinuclear antibodies in non-alcoholic steatohepatitis[J]. Hepatol Res, 2007, 37(11):923-931.